10 patents
Utility
Methods and Compositions for Preventing or Delaying Type 1 Diabetes
30 Nov 23
Provided herein, in one aspect, is a method of preventing or delaying the onset of clinical type 1 diabetes (T1D), comprising: administering a prophylactically effective amount of an anti-CD3 antibody to a non-diabetic subject who is at risk of T1D, wherein the prophylactically effective amount has a cumulative dose of about 10,500 μg/m2 to about 14,000 μg/m2.
Francisco Leon, Eleanor L. Ramos
Filed: 23 May 23
Utility
Methods for Delaying Onset of Type 1 Diabetes
19 Jan 23
Provided herein, in one aspect, is a method of preventing or delaying the onset of clinical type 1 diabetes (T1D), comprising: providing a non-diabetic subject who is at risk for T1D; determining that the non-diabetic subject (1) is substantially free of antibodies against zinc transporter 8 (ZnT8), (2) is HLA-DR4+, and/or (3) is not HLA-DR3+; and administering a prophylactically effective amount of an anti-CD3 antibody to the non-diabetic subject.
Francisco Leon, Kevan C. Herold, Jay S. Skyler
Filed: 2 Sep 22
Utility
Methods for Treating Type 1 Diabetes
1 Dec 22
Provided herein are a method of treating type 1 diabetes (T1D).
Francisco Leon, Ralph Raymond
Filed: 24 May 22
Utility
Methods for Treating Post Infectious Autoimmune Diabetes
24 Nov 22
Provided herein are a method of treating type 1 diabetes (T1D) post SARS-CoV-2 infection.
Francisco Leon
Filed: 24 May 22
Utility
Methods and compositions for preventing type 1 diabetes
6 Sep 22
Provided herein, in one aspect, is a method of preventing or delaying the onset of clinical type 1 diabetes (T1D), comprising: providing a non-diabetic subject who is at risk for T1D; determining that the non-diabetic subject (1) is substantially free of antibodies against zinc transporter 8 (ZnT8), (2) is HLA-DR4+, and/or (3) is not HLA-DR3+; and administering a prophylactically effective amount of an anti-CD3 antibody to the non-diabetic subject.
Francisco Leon, Kevan C. Herold, Jay S. Skyler
Filed: 14 May 20
Utility
Methods and Compositions for Treatment of Lupus
26 May 22
Disclosed herein, in one aspect, is a method of treating B cell driven autoimmune and allergic diseases, such as lupus, comprising administering to a patient in need thereof an effective amount of B cell inhibitor that is non-depletional.
Francisco Leon, Paul Dunford, Paul Moore
Filed: 1 Nov 21
Utility
Methods and Compositions for Preventing Type 1 Diabetes
10 Feb 22
Provided herein, in one aspect, is a method of preventing or delaying the onset of clinical type 1 diabetes (T1D), comprising: providing a non-diabetic subject who is at risk for T1D; administering a prophylactically effective amount of an anti-CD3 antibody to the non-diabetic subject; and determining, prior to or after the administering step, that the non-diabetic subject has more than about 5% to more than about 10% TIGIT+KLRG1+CD8+ T-cells in all CD3+ T cells, which is indicative of successful prevention or delay of the onset of clinical T1D.
Francisco Leon, Kevan C. Herold
Filed: 11 Jun 21
Utility
Methods and Compositions for Reducing Immunogenicity By Non-Depletional B Cell Inhibitors
6 May 21
Disclosed herein, in one aspect, is a method of reducing immunogenicity, comprising administering to a patient receiving or having received a biological therapeutic agent, an effective amount of B cell inhibitor that is non-depletional.
Francisco Leon, Paul Dunford
Filed: 7 Jan 21
Utility
Methods and Compositions for Reducing Immunogenicity By Non-Depletional B Cell Inhibitors
4 Feb 21
Disclosed herein, in one aspect, is a method of reducing immunogenicity, comprising administering to a patient receiving or having received a biological therapeutic agent, an effective amount of B cell inhibitor that is non-depletional.
Francisco Leon, Paul Dunford
Filed: 30 Jul 20
Utility
Methods and Compositions for Preventing Type 1 Diabetes
23 Dec 20
Provided herein, in one aspect, is a method of preventing or delaying the onset of clinical type 1 diabetes (T1D), comprising: providing a non-diabetic subject who is at risk for T1D; determining that the non-diabetic subject (1) is substantially free of antibodies against zinc transporter 8 (ZnT8), (2) is HLA-DR4+, and/or (3) is not HLA-DR3+; and administering a prophylactically effective amount of an anti-CD3 antibody to the non-diabetic subject.
Francisco Leon, Kevan C. Herold, Jay S. Skyler
Filed: 13 May 20
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first